Joint Venture - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
		Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2019	Jan. 31, 2019
Schedule Of Equity Method Investments [Line Items]
Elimination of equity method investment intra-entity profit on sales					$ 1,129
Total net revenue	[1]	$ 99,548		$ 103,221	287,951	$ 301,368
Accounts receivable from Joint Venture		334			334		$ 0
Gain (loss) on equity method investment, net		222			222
CNNC Accuray (Tianjin) Medical Technology Co. Ltd
Schedule Of Equity Method Investments [Line Items]
Total net revenue		6,145		$ 0	12,605	$ 0
Accounts receivable from Joint Venture		300			$ 300
Accuray Asia
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership interest in joint venture								49.00%
Gain on contribution to joint venture			$ 13,000
Elimination of equity method investment intra-entity profit on sales		$ 1,100
Proportion of recognizing joint venture income or loss					49.00%
CIRC Subsidiary
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership interest in joint venture								51.00%

[1] Includes sales to the China joint venture, an equity method investment of $6,145 and $12,605 for the three and nine months ended March 31, 2020 and $0 for both the three and nine months ended March 31, 2019, respectively. See Note 14.